Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
5e5 of anti-Carbonic Anhydrase IX CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human Carbonic Anhydrase IX (38-414) Protein, His Tag (Cat. No. CA9-HA2H7) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
2e5 of Anti-Carbonic Anhydrase IX CAR-293 cells were stained with 100 μL of 3 μg/mL of FITC-Labeled Human Carbonic Anhydrase IX (38-414), His Tag (Cat. No. CA9-HF228) and negative control protein respectively. FITC signal was used to evaluate the binding activity (QC tested).
Immobilized Anti-Carbonic Anhydrase IX Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human Carbonic Anhydrase IX (38-414), His Tag (Cat. No. CA9-HF228) with a linear range of 0.01-1.25 μg/mL (QC tested).
The purity of Cynomolgus Carbonic Anhydrase IX Protein, His Tag (Cat. No. CA9-C52H3) is more than 90% and the molecular weight of this protein is around 38-48 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Girentuximab-Zr-89 | TLX-250-CDx; 89Zr-TX-250; TLX250-CDx; 89Zr-TX250 | Phase 3 Clinical | Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Sarcoma; Cholangiocarcinoma; Contrast agents; Solid tumours; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms | Details | |
Lutetium-177 DOTA girentuximab | TLX-250 | Phase 2 Clinical | Heidelberg, Telix Pharmaceuticals Ltd | Solid tumours; Carcinoma, Renal Cell; Neoplasms | Details |
[177Lu]Lu-DPI-4452 | [177Lu]Lu-DPI-4452 | Phase 2 Clinical | Debiopharm International Sa | Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
Debio-0328 | [68Ga]Ga-DPI-4452; Gallium-68-DPI-4452 | Phase 2 Clinical | Debiopharm International Sa | Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
PMI-05 | PMI-05 | Phase 1 Clinical | Precision Molecular Inc | Neoplasms | Details |
Girentuximab | MAb-G250; cG250; WX-G250 | Phase 1 Clinical | Kidney Neoplasms; Carcinoma, Renal Cell | Details | |
PHC-102 | PHC102; 99mTc-CAIX | Phase 1 Clinical | Philochem | Carcinoma, Renal Cell | Details |
Indium-111-DOTA-girentuximab-IRDye800CW (Radboud University) | Phase 1 Clinical | Radboud University Nijmegen | Carcinoma, Renal Cell; Diagnostic agents | Details | |
CA9hu-1 | CA9hu-1 | Phase 1 Clinical | Mabpro AS | Head and Neck Neoplasms; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
Sulfamide-nitroimidazole | Clinical | Dualtpharma | Neoplasms | Details | |
Girentuximab-Zr-89 | TLX-250-CDx; 89Zr-TX-250; TLX250-CDx; 89Zr-TX250 | Phase 3 Clinical | Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Sarcoma; Cholangiocarcinoma; Contrast agents; Solid tumours; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms | Details | |
Lutetium-177 DOTA girentuximab | TLX-250 | Phase 2 Clinical | Heidelberg, Telix Pharmaceuticals Ltd | Solid tumours; Carcinoma, Renal Cell; Neoplasms | Details |
[177Lu]Lu-DPI-4452 | [177Lu]Lu-DPI-4452 | Phase 2 Clinical | Debiopharm International Sa | Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
Debio-0328 | [68Ga]Ga-DPI-4452; Gallium-68-DPI-4452 | Phase 2 Clinical | Debiopharm International Sa | Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal | Details |
PMI-05 | PMI-05 | Phase 1 Clinical | Precision Molecular Inc | Neoplasms | Details |
Girentuximab | MAb-G250; cG250; WX-G250 | Phase 1 Clinical | Kidney Neoplasms; Carcinoma, Renal Cell | Details | |
PHC-102 | PHC102; 99mTc-CAIX | Phase 1 Clinical | Philochem | Carcinoma, Renal Cell | Details |
Indium-111-DOTA-girentuximab-IRDye800CW (Radboud University) | Phase 1 Clinical | Radboud University Nijmegen | Carcinoma, Renal Cell; Diagnostic agents | Details | |
CA9hu-1 | CA9hu-1 | Phase 1 Clinical | Mabpro AS | Head and Neck Neoplasms; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
Sulfamide-nitroimidazole | Clinical | Dualtpharma | Neoplasms | Details |
This web search service is supported by Google Inc.